Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Rubèn Carrero Garcìa: Innovator in Cardiotoxicity Prediction
Introduction
Rubèn Carrero Garcìa is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Rubèn Carrero Garcìa holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention outlines an in vitro method for assessing the risk of cardiotoxicity by analyzing the expression levels of a specific combination of 10 circulating miRNAs in biological samples from patients. The identified miRNAs serve as biomarkers for predicting cardiotoxicity risk, thereby facilitating better management of chemotherapy treatments.
Career Highlights
Throughout his career, Rubèn has worked with esteemed institutions such as the Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has been instrumental in advancing the understanding of cardiotoxicity in cancer therapies.
Collaborations
Rubèn has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and validation of his innovative methodologies.
Conclusion
Rubèn Carrero Garcìa's contributions to the field of cardiotoxicity prediction represent a significant advancement in cancer treatment. His work not only enhances patient safety but also paves the way for future innovations in medical research.